SMA Niv denied for failing step therapy by Humana?

Humana's specific coverage criteria for sma niv are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied This Claim — and Why It's Appealable

A step-therapy ("fail-first") denial for non-invasive ventilation (NIV) in spinal muscular atrophy (SMA) means Humana is requiring documentation that less intensive respiratory support was tried and failed before approving NIV. In SMA, the clinical trajectory can make stepped trials medically inappropriate or dangerous — some patients cannot safely tolerate delay or a less effective modality. Step-therapy exceptions are a recognized and frequently successful appeal category, and many states have enacted step-therapy reform laws that further protect patients.

## Your Federal Appeal Rights

ACA §2719 provides the right to an internal appeal followed by independent external review through an IRO. ERISA §503 requires a full and fair review for employer plans. The external review window is generally four months from denial. When stepping through a less effective therapy would seriously jeopardize health, expedited review (often 72 hours) is available — this standard is frequently met in SMA with progressive respiratory failure. Additionally, check whether your state has a step-therapy override law: many states now require insurers to grant exceptions when the required step is contraindicated or clinically inappropriate for the specific patient.

## Concrete Appeal Steps

1. Identify exactly which step Humana requires and obtain the policy language governing exceptions. 2. Determine whether any prior respiratory support was already tried — if so, document it as satisfying the step. 3. If no prior step is possible, build a medical-exception argument: the prescribing physician must explain in writing why the required step is medically inappropriate, contraindicated, or would cause harm for this specific patient. 4. File a Level 1 internal appeal with the complete exception package. 5. Escalate to external review and, where applicable, invoke your state's step-therapy override statute.

## Documentation to Gather

• Diagnosis and severity: Genetic test confirming SMA type; pulmonologist or neurologist notes documenting respiratory muscle weakness, current functional status, and clinical trajectory.
• Prior treatment history: If any lesser respiratory support was used, provide dates, settings, duration, and outcome. If not, document why it was not clinically appropriate.
• Clinical urgency evidence: Pulmonary function results, sleep study data, blood gas values, and any acute respiratory events that support the prescriber's judgment that delay or step-down would be harmful.
• Prescriber medical-necessity letter: Detailed explanation of why NIV is the appropriate intervention now, referencing the FDA-cleared device labeling and the applicable guideline organization (e.g., AAN or ATS), and why the required step is not an appropriate intermediate for this patient.
• State law citation: If your state has a step-therapy exception statute, cite it explicitly in the appeal letter.

## Criteria-Mapping Structure

For each step-therapy requirement in Humana's policy, provide a direct chart citation or a physician explanation of why that step does not apply. Reviewers and IRO physicians respond to explicit, organized responses — a narrative that addresses each criterion in sequence is far more persuasive than a general letter asserting medical necessity.